COGT Cogent Biosciences, Inc.
Company Analysis
Latest News
Cogent Biosciences third quarter 2026 loss widens to $111.4M ahead of November PDUFA date
Cogent Biosciences reported a net loss of $111.4 million for the third quarter 2026 and generated no revenue, consistent with its pre-commercial stage. The...
Cogent Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 06, 2026
Analysts expect Cogent Biosciences to report a Q3 2026 net loss of $0.56 per share on zero revenue, with the current stock price of approximately $31.06...
Cogent Biosciences Enters Commercial Supply Agreement with Hovione for Bezuclastinib
Cogent Biosciences, Inc. has entered into a material Commercial Supply Agreement with Hovione FarmaCiencia S.A. to secure the manufacturing and supply of its...
OrbiMed Advisors boosts stake in Cogent Biosciences by over 420%
Healthcare investment firm OrbiMed Advisors significantly increased its position in Cogent Biosciences during the second quarter of 2026, boosting its stake by...
OrbiMed Adds Major Insurers, Exits Pfizer in Q2 2026 Reshuffle
Healthcare investment specialist OrbiMed Advisors filed its second-quarter 13F for 2026, revealing a portfolio valued at $5.40 billion. The firm's top holdings...